Regeneron Pharmaceuticals and Bayer HealthCare AG initiated a Phase III study of the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD). The study will compare the VEGF Trap-Eye and ranibizumab, Genentech’s Lucentis, an anti-angiogenic agent approved for wet AMD. The study will be conducted for the FDA’s Special Protocol Assessment (SPA). The VIEW 1 trial is expected to enroll approximately 1,200 patients in more than 200 centers throughout the ...